Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sells 2,695 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 2,695 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $25.44, for a total value of $68,560.80. Following the completion of the transaction, the insider now directly owns 43,165 shares in the company, valued at $1,098,117.60. The trade was a 5.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Sarah Aebersold also recently made the following trade(s):

• On Friday, March 14th, Sarah Aebersold sold 5,632 shares of BioLife Solutions stock. The stock was sold at an average price of $24.96, for a total value of $140,574.72.
• On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The stock was sold at an average price of $25.00, for a total value of $27,275.00.
• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total value of $6,484.80.

BioLife Solutions Stock Up 0.6 %

NASDAQ BLFS opened at $25.48 on Thursday. The stock’s 50 day moving average is $26.48 and its 200 day moving average is $25.49. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12 month low of $14.84 and a 12 month high of $29.55. The stock has a market cap of $1.20 billion, a PE ratio of -24.04 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The company had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. During the same period in the previous year, the firm earned ($0.21) EPS. Research analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Institutional Trading of BioLife Solutions

A number of large investors have recently added to or reduced their stakes in the company. Invesco Ltd. increased its stake in BioLife Solutions by 1.1% in the 4th quarter. Invesco Ltd. now owns 3,239,469 shares of the medical equipment provider’s stock worth $84,097,000 after acquiring an additional 36,176 shares during the last quarter. Fred Alger Management LLC increased its stake in BioLife Solutions by 1.0% in the 4th quarter. Fred Alger Management LLC now owns 1,594,221 shares of the medical equipment provider’s stock worth $41,386,000 after acquiring an additional 16,274 shares during the last quarter. State Street Corp increased its stake in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after acquiring an additional 95,788 shares during the last quarter. Millennium Management LLC increased its stake in BioLife Solutions by 49.1% in the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock worth $29,733,000 after acquiring an additional 377,111 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in BioLife Solutions by 4.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 887,008 shares of the medical equipment provider’s stock worth $23,028,000 after acquiring an additional 40,416 shares during the last quarter. Institutional investors own 93.24% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BLFS. Northland Securities lifted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. KeyCorp lifted their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. HC Wainwright lifted their price objective on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Benchmark reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. Finally, StockNews.com raised BioLife Solutions from a “sell” rating to a “hold” rating in a research report on Wednesday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.86.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.